Active Biotech AB (ACTI) - Total Assets
Based on the latest financial reports, Active Biotech AB (ACTI) holds total assets worth Skr58.20 Million SEK (≈ $6.26 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Active Biotech AB - Total Assets Trend (2000–2025)
This chart illustrates how Active Biotech AB's total assets have evolved over time, based on quarterly financial data. Also see Active Biotech AB market capitalisation for the company's overall valuation and market capitalisation.
Active Biotech AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Active Biotech AB's total assets of Skr58.20 Million consist of 96.3% current assets and 3.7% non-current assets. Review ACTI liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr65.10 Million | 92.7% |
| Accounts Receivable | Skr2.50 Million | 3.6% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr2.00 Million | 2.9% |
| Intangible Assets | Skr245.00K | 0.4% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2000–2025)
This chart illustrates how Active Biotech AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Active Biotech AB stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Active Biotech AB's current assets represent 96.3% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 92.7% of total assets in 2025, up from 11.5% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 5.0% in 2000.
- Asset Diversification: The largest asset category is cash and equivalents at 92.7% of total assets.
Active Biotech AB Competitors by Total Assets
Key competitors of Active Biotech AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
Active Biotech AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.14 | 2.87 | 9.19 |
| Quick Ratio | 5.14 | 2.87 | 9.56 |
| Cash Ratio | 0.00 | 2.54 | 8.82 |
| Working Capital | Skr45.10 Million | Skr19.30 Million | Skr72.90 Million |
Active Biotech AB - Advanced Valuation Insights
This section examines the relationship between Active Biotech AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.02 |
| Latest Market Cap to Assets Ratio | 0.18 |
| Asset Growth Rate (YoY) | 62.5% |
| Total Assets | Skr70.20 Million |
| Market Capitalization | $12.40 Million USD |
Valuation Analysis
Below Book Valuation: The market values Active Biotech AB's assets below their book value (0.18x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Active Biotech AB's assets grew by 62.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Active Biotech AB (2000–2025)
The table below shows the annual total assets of Active Biotech AB from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr70.20 Million ≈ $7.55 Million |
+62.50% |
| 2024-12-31 | Skr43.20 Million ≈ $4.65 Million |
-1.92% |
| 2023-12-31 | Skr44.05 Million ≈ $4.74 Million |
-13.64% |
| 2022-12-31 | Skr51.01 Million ≈ $5.49 Million |
-10.21% |
| 2021-12-31 | Skr56.80 Million ≈ $6.11 Million |
+76.66% |
| 2020-12-31 | Skr32.16 Million ≈ $3.46 Million |
-51.97% |
| 2019-12-31 | Skr66.95 Million ≈ $7.21 Million |
-77.86% |
| 2018-12-31 | Skr302.43 Million ≈ $32.55 Million |
-0.45% |
| 2017-12-31 | Skr303.81 Million ≈ $32.70 Million |
-26.42% |
| 2016-12-31 | Skr412.88 Million ≈ $44.43 Million |
-8.14% |
| 2015-12-31 | Skr449.44 Million ≈ $48.37 Million |
-37.80% |
| 2014-12-31 | Skr722.52 Million ≈ $77.75 Million |
-5.90% |
| 2013-12-31 | Skr767.81 Million ≈ $82.63 Million |
+10.20% |
| 2012-12-31 | Skr696.74 Million ≈ $74.98 Million |
-18.84% |
| 2011-12-31 | Skr858.52 Million ≈ $92.39 Million |
+70.65% |
| 2010-12-31 | Skr503.10 Million ≈ $54.14 Million |
+0.92% |
| 2009-12-31 | Skr498.50 Million ≈ $53.65 Million |
+5.40% |
| 2008-12-31 | Skr472.95 Million ≈ $50.90 Million |
-3.39% |
| 2007-12-31 | Skr489.54 Million ≈ $52.68 Million |
+5.87% |
| 2006-12-31 | Skr462.40 Million ≈ $49.76 Million |
-18.57% |
| 2005-12-31 | Skr567.86 Million ≈ $61.11 Million |
+81.49% |
| 2004-12-31 | Skr312.89 Million ≈ $33.67 Million |
-9.41% |
| 2003-12-31 | Skr345.40 Million ≈ $37.17 Million |
-26.12% |
| 2002-12-31 | Skr467.50 Million ≈ $50.31 Million |
-37.48% |
| 2001-12-31 | Skr747.74 Million ≈ $80.47 Million |
-13.95% |
| 2000-12-31 | Skr868.95 Million ≈ $93.51 Million |
-- |
About Active Biotech AB
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye disea… Read more